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Background
There is a growing number of potential new treatment
regimens for chronic lymphocytic leukaemia (CLL). As
there is limited number of patients, it is important that
statistical methodologies in Phase II trials efficiently
select promising regimens for subsequent evaluation in
a confirmatory, larger-scale Phase III trial.
Methods
In this study, we propose the screened selection
design, which combines two conventional Phase II trial
designs to provide a practical multi-stage approach for
evaluating the efficacy of two experimental arms in
high-risk CLL patients. Our aim is to select the most
promising regimen in terms of effectiveness to be
recommended for further testing. The proposed Phase
II randomised design is divided into two different seg-
ments. In the first segment, patients are randomised
equally into two experimental arms. By applying
Simon’s two-stage design [1] in each of the two paral-
lel experimental arms, this allows for initial determina-
tion of efficacy and early stopping for futility in any of
the arms. If there are an insufficient number of
responses in the first stage, recruitment will not con-
tinue for that particular arm. Otherwise, the study pro-
ceeds to stage 2 to randomize further patients to each
arm. The second segment of the study involves the
play-the-winner selection strategy as proposed by
Simon, Wittes and Ellenberg [2], which only applies if
results from both arms are found to be positive. Our
proposed design allows the treatment arm with the
highest response rates to be recommended only if the
efficacy rate is greater than a specified clinically-rele-
vant value. The number of subjects required for each
treatment arm in the first segment is selected to be as
close as possible to the number required for the selec-
tion strategy in the second segment according to pre-
specified error rates. The operating characteristics of
the trial design are explored via a simulation study.
Results
The proposed approach has the advantage of substan-
tial reduction in the probability of incorrectly selecting
an ineffective arm whose rates are not clinically signifi-
cant or when no true difference exists between the
arms. The only compromise is a slight reduction in the
probability of correctly selecting an effective treatment
arm if one exists. This approach is comparable to the
Bayesian Selection Strategy proposed by Estey and
Thall [3].
Conclusions
The proposed approach provides an easy to implement
Phase II design to select an effective and most promis-
ing treatment regimen for further testing in Phase III.
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